Related Experiment Video

Updated: Jun 13, 2026

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C

Alexandre Sampaio Moura1, Ricardo Andrade Carmo, Antonio Lucio Teixeira

  • 1Federal University of Minas Gerais, Brazil.

The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases
|April 30, 2010
PubMed

Insights

Peripheral inflammatory markers like cytokines and chemokines may predict liver damage and treatment success in Hepatitis C patients. Monitoring these markers aids in understanding disease progression and therapeutic outcomes.

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection is a significant global health issue, leading to cirrhosis and liver cancer.
  • The host's immune response, particularly T helper type 1 (Th1) cells, influences HCV disease progression and viral clearance after therapy.
  • Immune activation can be assessed via peripheral cytokines, chemokines (CCL5, CXCL10), and soluble tumor necrosis factor receptors (sTNF-R1, sTNF-R2).

Purpose of the Study:

  • To review the utility of peripheral inflammatory markers in predicting liver histological changes in chronic Hepatitis C.
  • To assess the role of these markers in forecasting therapeutic response in Hepatitis C patients.

Main Methods:

  • Literature review focusing on studies measuring peripheral inflammatory markers in chronic Hepatitis C patients.
  • Analysis of correlations between cytokine and chemokine levels and liver biopsy findings.
  • Evaluation of marker associations with treatment efficacy and viral elimination.

Main Results:

  • Peripheral inflammatory markers show potential as non-invasive indicators of liver disease severity.
  • Specific cytokines and chemokines may correlate with histological activity and fibrosis.
  • These markers could help predict the likelihood of successful antiviral therapy.

Conclusions:

  • Peripheral inflammatory markers offer a promising avenue for monitoring Hepatitis C progression and treatment outcomes.
  • Further research is warranted to validate these markers for clinical application in managing chronic Hepatitis C.

More Related Videos

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice08:32

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice

Published on: March 10, 2017

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...